Abstract 34P
Background
Social support is an important determinant of optimal care and maybe extended by community partners including non-governmental organizations to enhance the well-being of individuals living with cancer. We determined whether social support mediated the association between unmet needs and happiness in women with early breast cancer in a multiethnic Asian setting.
Methods
The study employed a hospital-based cross-sectional design that recruited 400 multiethnic patients newly diagnosed with early breast cancer in seven tertiary Malaysian hospitals. Study tools included Multi-dimensional Scale of Perceived Social Support, Needs Assessment Tool for Breast Cancer and Oxford, Happiness Questionnaire. Partial least square structural equation modelling was used to determine the mediating role of social support in the association between unmet needs and happiness.
Results
Participants comprised Malays (58.3%), followed by Chinese (26.8%), and Indians (12.3%). Two-thirds were recruited from Ministry of Health-owned hospitals, 20.5% from academic and 14.8% from private hospitals. A majority were diagnosed with stage II (32.3%) or stage III (30.0%) breast cancer at initial diagnosis. About 5.3% of participants reported to be unhappy, 5.8% somewhat unhappy, 8.3% rather unhappy, 30.3% somewhat happy, 28.7% rather happy, and 21.8% happy. A majority had moderate-level unmet supportive care needs (74%), with the highest level of unmet needs in the domains of information services (31.3%) and hospital appointments (30.3%). Sixty per cent reported a high level of social support. Unmet needs were found to have a negative and significant effect on happiness (f 2 =8.0%, β = −0.259, p < 0.001). Social support significantly, positively, and partially mediated the association between unmet needs and, with the p-values significant for both direct (p < 0.001) and indirect (p = 0.024) effects.
Conclusions
Social support plays an important role in bridging unmet needs and improving well-being of women with breast cancer. Study findings are expected to foster greater public-private partnerships in engaging communities to actively play a role in improving life after (breast) cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Ministry of Higher Education, Malaysia.
Disclosure
R. Kaur: Financial Interests, Personal, Speaker, Consultant, Advisor: Novartis, AstraZeneca, Pfizer, Roche,. M. Thiagarajan: Non-Financial Interests, Institutional, Leadership Role: Malaysian Oncological Society, President. N.F. Bt Abdul Satar: Financial Interests, Personal, Advisory Board: Novartis, Zuellig Pharma,Ipsen Pharma, Eisai, MSD Malaysia,Pfizer, Roche,; Financial Interests, Personal, Funding: KURA Oncology, Viracta Therapeutics, MSD Malaysia, Naluri Sdn Bhd; Financial Interests, Institutional, Principal Investigator: KURA Oncology, Viracta Therapeutics, MSD Malaysia, Naluri Sdn Bhd; Non-Financial Interests, Personal, Leadership Role: Project Lead for Cancer ECHO UM. A. Ali: Financial Interests, Personal, Invited Speaker: Roche, AstraZeneca. F.L.T. Chong: Financial Interests, Personal, Invited Speaker: Novartis, Roche,; Financial Interests, Personal and Institutional, Principal Investigator: Novartis, J&J. A.F. Abdul Aziz: Financial Interests, Personal, Invited Speaker: Roche; Non-Financial Interests, Institutional, Member of Board of Directors: National Cancer Society Malaysia; Non-Financial Interests, Institutional, Member: Fellow of College of Surgeons, Academy of Medicine Malaysia Member of Malaysian Oncological Society. C.H. Yip: Financial Interests, Personal, Advisory Board: AstraZeneca. N. Bhoo-Pathy: Financial Interests, Personal, Funding: Partial funding from Ministry of Higher Education. All other authors have declared no conflicts of interest.
Resources from the same session
415P - Initial experience in a real-world Asian cohort with a circulating tumor DNA (ctDNA) mutation-based multi-cancer early detection (MCED) assay
Presenter: Steven Tucker
Session: Poster Display
Resources:
Abstract
416P - Three-dimensional bioprinting model of ovarian cancer for identification of patient-specific therapy response
Presenter: Jiangang Zhang
Session: Poster Display
Resources:
Abstract
417P - Early experience in using plasma-only multi-omic minimal residual disease testing in early-stage colorectal cancer patients from Asia and the Middle East
Presenter: Shaheenah Dawood
Session: Poster Display
Resources:
Abstract
418P - Decoding the intricate cellular makeup of immune-related adverse events using single-cell and spatial analysis
Presenter: Dmitrii Shek
Session: Poster Display
Resources:
Abstract
420P - Combinatory genomic and transcriptomic sequencing of Chinese KRAS mutant non-small cell lung cancer revealed molecular and inflammatory heterogeneity in tumor microenvironment
Presenter: Xuchao Zhang
Session: Poster Display
Resources:
Abstract
421P - Comprehensive genomic profiling (CGP) unravels somatic BRCA (sBRCA) and homologous recombinant repair (HRR) gene alterations across multi-cancer spectrum
Presenter: Ramya Kodandapani
Session: Poster Display
Resources:
Abstract
422P - CD8Teff distinguished tumor immunotyping heterogeneity and enables precision immunotherapy
Presenter: luhui Mao
Session: Poster Display
Resources:
Abstract
423P - Insights into clinically actionable biomarkers in an Indian cancer cohort of 1000 patients using comprehensive genomic profiling (CGP)
Presenter: Mithua Ghosh
Session: Poster Display
Resources:
Abstract
424P - MD Anderson Cancer Center global precision oncology decision support (Glo-PODS) clinical trial genomic support: Pilot program at the Prince of Wales Hospital (Chinese University of Hong Kong - CUHK)
Presenter: Brigette Ma
Session: Poster Display
Resources:
Abstract
425P - Engineered <italic>Lactococcus lactis</italic> as a personalized cancer vaccine platform induces antitumour immunity via membrane-inserted peptide for neoantigens
Presenter: Meng Zhu
Session: Poster Display
Resources:
Abstract